Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bogus DME dealers accused of healthcare fraud

This article was originally published in The Gray Sheet

Executive Summary

Eight individuals are charged in Miami federal court with forming bogus durable medical equipment companies and knowingly billing Medicare for services and products which were not provided. The charges stem from a two-and-a-half year investigation by the U.S. Attorney for the Southern District of Florida, FBI healthcare fraud squad and the IRS. A maximum penalty of 10 years' imprisonment and fines of up to twice the amount defrauded from Medicare may apply. DME includes devices such as wheelchairs, for which a targeted anti-fraud campaign was launched by CMS and OIG Sept. 9 (1"The Gray Sheet" Sept. 15, 2003, p. 4)...

You may also be interested in...



Power Wheelchairs Targeted For Inherent Reasonableness Price Adjustments

CMS plans to develop inherent reasonableness review guidelines to ensure appropriate Medicare payments for motorized wheelchairs as part of a larger initiative to curb provider billing fraud, the agency says

EU Ministers Want Decisive Action On Medicines Access & Shortages

Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.

Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab

China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.

UsernamePublicRestriction

Register

MT019028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel